<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18387724</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>05</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>07</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0278-5846</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>32</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>May</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title>
                <ISOAbbreviation>Prog. Neuropsychopharmacol. Biol. Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Risperidone-induced double incontinence.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1085-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2008.02.007</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Herg√ºner</LastName>
                    <ForeName>Sabri</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mukaddes</LastName>
                    <ForeName>Nahit Motavalli</ForeName>
                    <Initials>NM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>02</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA>
            <NlmUniqueID>8211617</NlmUniqueID>
            <ISSNLinking>0278-5846</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>L6UH7ZF8HC</RegistryNumber>
                <NameOfSubstance UI="D018967">Risperidone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001321">Autistic Disorder</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005242">Fecal Incontinence</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008607">Intellectual Disability</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018967">Risperidone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016728">Self-Injurious Behavior</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014549">Urinary Incontinence</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2007</Year>
                <Month>6</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0278-5846(08)00066-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pnpbp.2008.02.007</ArticleId>
            <ArticleId IdType="pubmed">18387724</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18662289</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>12</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of clinical pharmacology</Title>
                <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>517-28</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2125.2008.03248.x</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To examine the allelic variation of three enzymes involved in 6-mercaptopurine/azathioprine (6-MP/AZA) metabolism and evaluate the influence of these polymorphisms on toxicity, haematological parameters and metabolite levels in patients with acute lymphoblastic leukaemia (ALL) or inflammatory bowel disease (IBD).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Clinical data and blood samples were collected from 19 ALL paediatric patients and 35 IBD patients who were receiving 6-MP/AZA therapy. All patients were screened for seven genetic polymorphisms in three enzymes involved in mercaptopurine metabolism [xanthine oxidase, inosine triphosphatase (C94--&gt;A and IVS2+21A--&gt;C) and thiopurine methyltransferase]. Erythrocyte and plasma metabolite concentrations were also determined. The associations between the various genotypes and myelotoxicity, haematological parameters and metabolite concentrations were determined.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Thiopurine methyltransferase variant alleles were associated with a preferential metabolism away from 6-methylmercaptopurine nucleotides (P = 0.008 in ALL patients, P = 0.038 in IBD patients) favouring 6-thioguanine nucleotides (6-TGNs) (P = 0.021 in ALL patients). Interestingly, carriers of inosine triphosphatase IVS2+21A--&gt;C variants among ALL and IBD patients had significantly higher concentrations of the active cytotoxic metabolites, 6-TGNs (P = 0.008 in ALL patients, P = 0.047 in IBD patients). The study confirmed the association of thiopurine methyltransferase heterozygosity with leucopenia and neutropenia in ALL patients and reported a significant association between inosine triphosphatase IVS2+21A--&gt;C variants with thrombocytopenia (P = 0.012). CONCLUSIONS; Pharmacogenetic polymorphisms in the 6-MP pathway may help identify patients at risk for associated toxicities and may serve as a guide for dose individualization.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hawwa</LastName>
                    <ForeName>Ahmed F</ForeName>
                    <Initials>AF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical and Practice Research Group, School of Pharmacy, Medical Biology Centre, Queen's University Belfast, Belfast, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Millership</LastName>
                    <ForeName>Jeff S</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collier</LastName>
                    <ForeName>Paul S</ForeName>
                    <Initials>PS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vandenbroeck</LastName>
                    <ForeName>Koen</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McCarthy</LastName>
                    <ForeName>Anthony</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dempsey</LastName>
                    <ForeName>Sid</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cairns</LastName>
                    <ForeName>Carole</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collins</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rodgers</LastName>
                    <ForeName>Colin</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McElnay</LastName>
                    <ForeName>James C</ForeName>
                    <Initials>JC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>06</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>7503323</NlmUniqueID>
            <ISSNLinking>0306-5251</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006150">Guanine Nucleotides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013873">Thionucleotides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>15867-02-4</RegistryNumber>
                <NameOfSubstance UI="C003964">6-thioguanylic acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E7WED276I5</RegistryNumber>
                <NameOfSubstance UI="D015122">6-Mercaptopurine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.1.1.-</RegistryNumber>
                <NameOfSubstance UI="D008780">Methyltransferases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.1.1.67</RegistryNumber>
                <NameOfSubstance UI="C022745">thiopurine methyltransferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MRK240IY2L</RegistryNumber>
                <NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 1999 Dec 1;91(23):1983-5</RefSource>
                <PMID Version="1">10580012</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2000 Jun;118(6):1025-30</RefSource>
                <PMID Version="1">10833476</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Biochem. 2001 Feb;34(1):9-16</RefSource>
                <PMID Version="1">11239509</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 2001 Apr;29(4 Pt 2):601-5</RefSource>
                <PMID Version="1">11259360</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 2001;52 Suppl 1:75S-87S</RefSource>
                <PMID Version="1">11564055</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2002 Apr;50(4):485-9</RefSource>
                <PMID Version="1">11889067</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2002 Aug;51(2):143-6</RefSource>
                <PMID Version="1">12117866</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Genet. 2002 Oct;111(4-5):360-7</RefSource>
                <PMID Version="1">12384777</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Best Pract Res Clin Gastroenterol. 2003 Feb;17(1):37-46</RefSource>
                <PMID Version="1">12617881</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Inflamm Bowel Dis. 2003 Jan;9(1):34-58</RefSource>
                <PMID Version="1">12656136</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rev Gastroenterol Disord. 2003;3 Suppl 1:S30-8</RefSource>
                <PMID Version="1">12684587</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rev Gastroenterol Disord. 2003 Summer;3(3):150-7</RefSource>
                <PMID Version="1">14502119</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pharmacogenomics. 2003;3(6):361-70</RefSource>
                <PMID Version="1">14672516</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Haematol. 2004 May;125(4):421-34</RefSource>
                <PMID Version="1">15142113</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenetics. 2004 Mar;14(3):181-7</RefSource>
                <PMID Version="1">15167706</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2004 Jun;26(3):311-8</RefSource>
                <PMID Version="1">15167634</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenetics. 2004 Jul;14(7):407-17</RefSource>
                <PMID Version="1">15226673</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2004 Apr;26(2):220-6</RefSource>
                <PMID Version="1">15228169</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1983 Apr 28;308(17):1005-9</RefSource>
                <PMID Version="1">6572786</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1984 Jan 10;259(1):12-5</RefSource>
                <PMID Version="1">6608520</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMJ. 1990 Jan 27;300(6719):230-5</RefSource>
                <PMID Version="1">2106931</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1990 Jul 28;336(8709):225-9</RefSource>
                <PMID Version="1">1973780</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 1991 Dec;50(6):663-72</RefSource>
                <PMID Version="1">1752110</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 1992;43(4):329-39</RefSource>
                <PMID Version="1">1451710</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pediatr Hematol Oncol. 1993 Feb;15(1):80-6</RefSource>
                <PMID Version="1">8447563</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1993 May 1;341(8853):1151</RefSource>
                <PMID Version="1">8097831</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1994 Nov 29;48(11):2135-8</RefSource>
                <PMID Version="1">7802704</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 1995 Feb;13(2):345-51</RefSource>
                <PMID Version="1">7531219</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1995 Apr 1;85(7):1897-902</RefSource>
                <PMID Version="1">7703493</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1995 Apr 15;55(8):1670-4</RefSource>
                <PMID Version="1">7712473</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 1995 Jun;47(6):1141-7</RefSource>
                <PMID Version="1">7603453</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1997 Apr 15;126(8):608-14</RefSource>
                <PMID Version="1">9103127</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 1998 Jul;63(1):11-6</RefSource>
                <PMID Version="1">9634537</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1998 Nov 1;129(9):716-8</RefSource>
                <PMID Version="1">9841604</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1999 Feb;47(2):131-43</RefSource>
                <PMID Version="1">10190647</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1999 May 1;93(9):2817-23</RefSource>
                <PMID Version="1">10216075</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Haematol. 1999 Jun;105(3):696-700</RefSource>
                <PMID Version="1">10354134</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1963 Sep;23:1202-6</RefSource>
                <PMID Version="1">14070376</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1393-7</RefSource>
                <PMID Version="1">15571265</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2005 Apr;54(4):565</RefSource>
                <PMID Version="1">15753546</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Gastroenterol Hepatol. 2005 Aug;20(8):1149-57</RefSource>
                <PMID Version="1">16048561</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Intern Med J. 2005 Oct;35(10):580-5</RefSource>
                <PMID Version="1">16207256</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterol Clin Biol. 2005 Dec;29(12):1264-9</RefSource>
                <PMID Version="1">16518285</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2006 Mar 13;25(11):1629-38</RefSource>
                <PMID Version="1">16550163</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Aliment Pharmacol Ther. 2006 Sep 1;24(5):715-29</RefSource>
                <PMID Version="1">16918876</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015122">6-Mercaptopurine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000964">Antimetabolites, Antineoplastic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001379">Azathioprine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005787">Gene Frequency</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006150">Guanine Nucleotides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015212">Inflammatory Bowel Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008780">Methyltransferases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010597">Pharmacogenetics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011110">Polymorphism, Genetic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054198">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013873">Thionucleotides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2561120</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">BCP3248</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2125.2008.03248.x</ArticleId>
            <ArticleId IdType="pubmed">18662289</ArticleId>
            <ArticleId IdType="pmc">PMC2561120</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3609047</PMID>
        <DateCreated>
            <Year>1987</Year>
            <Month>09</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1987</Year>
            <Month>09</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0195-668X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1987</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European heart journal</Title>
                <ISOAbbreviation>Eur. Heart J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Torsade de pointes during loading with amiodarone.</ArticleTitle>
            <Pagination>
                <MedlinePgn>541-3</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Torsade de pointes represents a potential complication of chronic amiodarone therapy. Several reports have emphasized the need for a loading dose in order to achieve therapeutic blood levels rapidly. We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter. Torsades de pointes were preceded and associated with marked QT prolongation and bradycardia. This report suggests that careful monitoring of patients undergoing oral amiodarone loading is necessary.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Leroy</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haiat</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barthelemy</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lionnet</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Eur Heart J</MedlineTA>
            <NlmUniqueID>8006263</NlmUniqueID>
            <ISSNLinking>0195-668X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>N3RQ532IUT</RegistryNumber>
                <NameOfSubstance UI="D000638">Amiodarone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000638">Amiodarone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001282">Atrial Flutter</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002304">Cardiac Pacing, Artificial</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007262">Infusions, Intravenous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008133">Long QT Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013610">Tachycardia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1987</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1987</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1987</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3609047</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12465074</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>03</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0885-3185</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Movement disorders : official journal of the Movement Disorder Society</Title>
                <ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1312-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A wide range of motor fluctuations develop in Parkinson's disease (PD) patients after prolonged levodopa (L-dopa) treatment, but few experimental models exist in which these can be investigated. We report on motor fluctuations occurring in MPTP-treated common marmosets (Callithrix jacchus) treated repeatedly with L-dopa. All animals showed an improvement in motor function in response to L-dopa, and rapidly developed peak-dose dyskinesia. During the period of L-dopa action, brief periods of immobility were occasionally observed. After acute L-dopa challenge, animals exhibited a worsening of motor function before improvement, and after the beneficial response to L-dopa declined, motor performance showed rebound worsening to below-baseline values. Before L-dopa challenge and during wearing-off and rebound worsening, leg dystonias were observed. Although these findings cannot necessarily be generalized to all MPTP-treated nonhuman primates, they demonstrate that MPTP-treated marmosets show a range of different motor fluctuations analogous to those seen in PD patients chronically treated with L-dopa. Therefore, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates can provide a model in which the pathophysiology of treatment complications can be investigated.</AbstractText>
                <CopyrightInformation>Copyright 2002 Movement Disorder Society</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kuoppam√§ki</LastName>
                    <ForeName>Mikko</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurodegenerative Diseases Research Centre, King's College, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Al-Barghouthy</LastName>
                    <ForeName>Ghassan</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jackson</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Lance</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeng</LastName>
                    <ForeName>Bai-Yun</ForeName>
                    <Initials>BY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quinn</LastName>
                    <ForeName>Niall</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jenner</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mov Disord</MedlineTA>
            <NlmUniqueID>8610688</NlmUniqueID>
            <ISSNLinking>0885-3185</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>46627O600J</RegistryNumber>
                <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9P21XSP91P</RegistryNumber>
                <NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002144">Callithrix</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009048">Motor Skills</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12465074</ArticleId>
            <ArticleId IdType="doi">10.1002/mds.10263</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">847814</PMID>
        <DateCreated>
            <Year>1977</Year>
            <Month>05</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1977</Year>
            <Month>05</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0041-5782</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>139</Volume>
                    <Issue>13</Issue>
                    <PubDate>
                        <Year>1977</Year>
                        <Month>Mar</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Ugeskrift for laeger</Title>
                <ISOAbbreviation>Ugeskr. Laeg.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Acute dystonia in children and young people caused by metoclopramide (Primperan). 2 cases from a casualty department].</ArticleTitle>
            <Pagination>
                <MedlinePgn>763-4</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Heilmann</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Risbo</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>dan</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Akut dystoni hos b√∏rn og unge for√•rsaget af metoklopramid (Primperan). To tilfaelde fra skadestue</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>DENMARK</Country>
            <MedlineTA>Ugeskr Laeger</MedlineTA>
            <NlmUniqueID>0141730</NlmUniqueID>
            <ISSNLinking>0041-5782</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>L4YEB44I46</RegistryNumber>
                <NameOfSubstance UI="D008787">Metoclopramide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008787">Metoclopramide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009129">Muscle Tonus</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009135">Muscular Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1977</Year>
                <Month>3</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1977</Year>
                <Month>3</Month>
                <Day>28</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1977</Year>
                <Month>3</Month>
                <Day>28</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">847814</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2371197</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0032-5473</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>66</Volume>
                    <Issue>775</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Postgraduate medical journal</Title>
                <ISOAbbreviation>Postgrad Med J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Embolic stroke following cardioversion of atrial fibrillation to sinus rhythm with oral amiodarone therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>410</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yapa</LastName>
                    <ForeName>R S</ForeName>
                    <Initials>RS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Green</LastName>
                    <ForeName>G J</ForeName>
                    <Initials>GJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Postgrad Med J</MedlineTA>
            <NlmUniqueID>0234135</NlmUniqueID>
            <ISSNLinking>0032-5473</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>N3RQ532IUT</RegistryNumber>
                <NameOfSubstance UI="D000638">Amiodarone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurology. 1978 Oct;28(10):973-7</RefSource>
                <PMID Version="1">570666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Heart J. 1982 Sep;104(3):617-21</RefSource>
                <PMID Version="1">7113903</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Heart J. 1986 Nov;112(5):1039-43</RefSource>
                <PMID Version="1">3776800</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Neurol. 1986 Feb;19(2):158-61</RefSource>
                <PMID Version="1">3963758</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Stroke. 1983 Sep-Oct;14(5):664-7</RefSource>
                <PMID Version="1">6658948</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000638">Amiodarone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001281">Atrial Fibrillation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002561">Cerebrovascular Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2426838</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2371197</ArticleId>
            <ArticleId IdType="pmc">PMC2426838</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15956868</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>06</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>10</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0196-206X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>26</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of developmental and behavioral pediatrics : JDBP</Title>
                <ISOAbbreviation>J Dev Behav Pediatr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of prenatal cocaine/polydrug use on maternal-infant feeding interactions during the first year of life.</ArticleTitle>
            <Pagination>
                <MedlinePgn>194-200</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The effects of prenatal cocaine use on quality of maternal-infant interactions were evaluated using the Nursing Child Assessment Feeding Scale (NCAFS). A total of 341 (155 cocaine using; 186 non-cocaine using) low socioeconomic, primarily African-American dyads were evaluated longitudinally at birth, 6.5, and 12 months. Group differences over time were examined, controlling for covariates, using a mixed-model linear approach. Women who used cocaine during pregnancy were less sensitive to their infants than non-cocaine-using women at 6.5 and 12 months. At 6.5 months, heavier prenatal cocaine users were less responsive to their infants than lighter users. In infants, prenatal cocaine exposure was related to poorer clarity of cues. There were no significant cocaine effects on maternal social-emotional growth fostering, cognitive growth fostering, or infant responsiveness to mother. Controlling for covariates, concentration of cocaine metabolites predicted maternal sensitivity to infant cues and infant clarity of cues at 1 year. Maternal cocaine use during pregnancy and other pre- and postnatal factors adversely affect maternal-infant interactions during the first year of life.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Minnes</LastName>
                    <ForeName>Sonia</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Medical Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, USA. sonia.minnes@case.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singer</LastName>
                    <ForeName>Lynn T</ForeName>
                    <Initials>LT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arendt</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Satayathum</LastName>
                    <ForeName>Sudtida</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 DA007957</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DA007957-12</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01-07259</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01-07957</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RR00080</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Dev Behav Pediatr</MedlineTA>
            <NlmUniqueID>8006933</NlmUniqueID>
            <ISSNLinking>0196-206X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013287">Street Drugs</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2000 Sep-Oct;22(5):653-66</RefSource>
                <PMID Version="1">11106858</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Drug Alcohol Abuse. 1992;18(2):131-44</RefSource>
                <PMID Version="1">1562011</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Neurosci. 1991 Mar;57(1-2):73-9</RefSource>
                <PMID Version="1">1938157</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Psychopathol. 1999 Fall;11(4):715-25</RefSource>
                <PMID Version="1">10624722</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Perinat Neonatal Nurs. 1992 Dec;6(3):76-84</RefSource>
                <PMID Version="1">1295967</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatrics. 1994 Feb;93(2):254-60</RefSource>
                <PMID Version="1">8121737</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Toxicol Clin Toxicol. 1994;32(6):697-703</RefSource>
                <PMID Version="1">7966527</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Subst Abuse. 1995;7(2):165-74</RefSource>
                <PMID Version="1">7580227</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 1995 Jul-Aug;17(4):403-11</RefSource>
                <PMID Version="1">7565486</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Psychobiol. 1996 Jul;29(5):463-80</RefSource>
                <PMID Version="1">8809496</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Psychol. 1997 Apr;53(3):279-87</RefSource>
                <PMID Version="1">9075056</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Psychol. 1998 May;34(3):555-64</RefSource>
                <PMID Version="1">9597364</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neuropsychiatry Clin Neurosci. 1999 Summer;11(3):361-9</RefSource>
                <PMID Version="1">10440013</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 1991 Mar-Apr;13(2):229-33</RefSource>
                <PMID Version="1">2046640</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pediatr. 1989 Sep;115(3):474-7</RefSource>
                <PMID Version="1">2769510</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Obstet Gynecol. 1989 May;160(5 Pt 1):1107-11</RefSource>
                <PMID Version="1">2729387</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>New Dir Child Dev. 1989 Spring;(43):49-61</RefSource>
                <PMID Version="1">2710392</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Child Dev. 1988 Jun;59(3):554-70</RefSource>
                <PMID Version="1">3383667</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pers Soc Psychol. 1986 Dec;51(6):1173-82</RefSource>
                <PMID Version="1">3806354</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Child Dev. 1983 Oct;54(5):1199-210</RefSource>
                <PMID Version="1">6354627</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Child Dev. 1982 Oct;53(5):1134-56</RefSource>
                <PMID Version="1">7140423</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Obstet Gynecol. 1973 Sep 1;117(1):1-9</RefSource>
                <PMID Version="1">4722373</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Dis Child Fetal Neonatal Ed. 2003 Sep;88(5):F391-9</RefSource>
                <PMID Version="1">12937043</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Dev Behav Pediatr. 2003 Aug;24(4):233-41</RefSource>
                <PMID Version="1">12915795</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatrics. 2002 Dec;110(6):1182-92</RefSource>
                <PMID Version="1">12456917</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Dev Behav Pediatr. 2002 Aug;23(4):191-202</RefSource>
                <PMID Version="1">12177564</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2002 May-Jun;24(3):385-95</RefSource>
                <PMID Version="1">12009493</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2002 May-Jun;24(3):329-37</RefSource>
                <PMID Version="1">12009488</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2002 Mar-Apr;24(2):127-35</RefSource>
                <PMID Version="1">11943500</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Child Psychol Psychiatry. 2002 Jan;43(1):81-102</RefSource>
                <PMID Version="1">11848338</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Neurosci. 2001 Sep;110(1-2):55-72</RefSource>
                <PMID Version="1">11697211</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Subst Abuse Treat. 2001 Mar;20(2):143-51</RefSource>
                <PMID Version="1">11306217</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044383">African Continental Ancestry Group</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016241">Child of Impaired Parents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000208">ethnology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D005247">Feeding Behavior</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008425">Maternal Behavior</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009034">Mother-Child Relations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016487">Parenting</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013287">Street Drugs</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS80352</OtherID>
        <OtherID Source="NLM">PMC2593854</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">00004703-200506000-00005</ArticleId>
            <ArticleId IdType="pubmed">15956868</ArticleId>
            <ArticleId IdType="pmc">PMC2593854</ArticleId>
            <ArticleId IdType="mid">NIHMS80352</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18721220</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1468-3083</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the European Academy of Dermatology and Venereology : JEADV</Title>
                <ISOAbbreviation>J Eur Acad Dermatol Venereol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Reversible ageusia as an adverse effect of hydroxychloroquine treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>604-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1468-3083.2008.02984.x</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fleury</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Droitcourt</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Polard</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chevrant-Breton</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Eur Acad Dermatol Venereol</MedlineTA>
            <NlmUniqueID>9216037</NlmUniqueID>
            <ISSNLinking>0926-9959</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>4QWG6N8QKH</RegistryNumber>
                <NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000370">Ageusia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006886">Hydroxychloroquine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008180">Lupus Erythematosus, Systemic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011248">Pregnancy Complications</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>6</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JDV2984</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1468-3083.2008.02984.x</ArticleId>
            <ArticleId IdType="pubmed">18721220</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3864349</PMID>
        <DateCreated>
            <Year>1985</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1985</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2008</Year>
            <Month>02</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0365-5237</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>423</Volume>
                    <PubDate>
                        <Year>1985</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Acta oto-laryngologica. Supplementum</Title>
                <ISOAbbreviation>Acta Otolaryngol Suppl</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Histopathological features of the spiral ganglion and cochlear nerve in temporal bones from three patients with profound hearing loss.</ArticleTitle>
            <Pagination>
                <MedlinePgn>59-66</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In the following study the condition of the spiral ganglion and the cochlear nerve of ears from patients suffering from profound hearing loss is described. The number of spiral ganglion cells has been related to the clinical diagnosis. The number of spiral ganglion cells in the two temporal bones of a patient with Neomycin ototoxicity was almost normal. A reduction of less than one-third of spiral ganglion cells has been observed in the temporal bones of a child who died after a bacterial labyrinthitis. The temporal bone with a Mondini dysplasia revealed a pronounced reduction of ganglion cells of more than two-thirds. The cochlear nerve trunk in the internal auditory canal appeared normal in all three cases. The present findings are discussed in respect to the degenerative behaviour of the cochlear neural elements in human being compared to animals.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pollak</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Felix</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>SWEDEN</Country>
            <MedlineTA>Acta Otolaryngol Suppl</MedlineTA>
            <NlmUniqueID>0370355</NlmUniqueID>
            <ISSNLinking>0365-5237</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>1404-04-2</RegistryNumber>
                <NameOfSubstance UI="D009355">Neomycin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003051">Cochlea</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000002">abnormalities</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003056">Cochlear Nerve</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003638">Deafness</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007762">Labyrinthitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009355">Neomycin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013136">Spiral Ganglion</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013701">Temporal Bone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1985</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1985</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1985</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3864349</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2910042</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>02</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>02</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-922X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>143</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of diseases of children (1960)</Title>
                <ISOAbbreviation>Am. J. Dis. Child.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Passive freebase cocaine ('crack') inhalation by infants and toddlers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>25-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Cocaine and its principal metabolite, benzoyl ecgonine, were isolated from the urine of four hospitalized children who had been exposed to the smoke of freebase cocaine (&quot;crack&quot;) used by their adult caretakers. Two of the children had transient neurological symptoms (drowsiness and unsteady gait) and two had seizures whose cause could not be determined by laboratory investigation. Passive cocaine inhalation may have caused or contributed to these symptoms. Children in the care of adults who abuse freebase cocaine should be considered at risk not only for disruption of their social environment but also for the effects of cocaine toxicity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bateman</LastName>
                    <ForeName>D A</ForeName>
                    <Initials>DA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heagarty</LastName>
                    <ForeName>M C</ForeName>
                    <Initials>MC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Dis Child</MedlineTA>
            <NlmUniqueID>0370471</NlmUniqueID>
            <ISSNLinking>0002-922X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012906">Smoke</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005684">Gait</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012894">Sleep Stages</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012906">Smoke</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2910042</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6800515</PMID>
        <DateCreated>
            <Year>1982</Year>
            <Month>05</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1982</Year>
            <Month>05</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0267-0623</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>284</Volume>
                    <Issue>6314</Issue>
                    <PubDate>
                        <Year>1982</Year>
                        <Month>Feb</Month>
                        <Day>13</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British medical journal (Clinical research ed.)</Title>
                <ISOAbbreviation>Br Med J (Clin Res Ed)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Paracetamol-induced acute renal failure in the absence of fulminant liver damage.</ArticleTitle>
            <Pagination>
                <MedlinePgn>505-6</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gabriel</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br Med J (Clin Res Ed)</MedlineTA>
            <NlmUniqueID>8302911</NlmUniqueID>
            <ISSNLinking>0267-0623</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>362O9ITL9D</RegistryNumber>
                <NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Medicine (Baltimore). 1979 Sep;58(5):362-76</RefSource>
                <PMID Version="1">481195</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000082">Acetaminophen</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058186">Acute Kidney Injury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1496049</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1982</Year>
                <Month>2</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1982</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1982</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6800515</ArticleId>
            <ArticleId IdType="pmc">PMC1496049</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14556027</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>11</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>03</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0179-0358</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pediatric surgery international</Title>
                <ISOAbbreviation>Pediatr. Surg. Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Enteral glutamine supplementation and dexamethasone attenuate the local intestinal damage in rats with experimental necrotizing enterocolitis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>578-82</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The pathogenesis of necrotizing enterocolitis (NEC) presumptively is due to an inappropriate intestinal epithelial immunologic response of immature gut to luminal stimuli. Glutamine is essential for intestinal crypt cell proliferation and enhances the cellular response to growth factors. We aimed to test the hypothesis that the supplementation of enteral feedings with glutamine may stimulate an immature intestine and decrease the intestinal inflammatory change in NEC. Immediately after birth, the neonatal rats were weighed and randomized into one of four treatment groups. Group 1 consisted of rats whom were breast-fed. Group 2 (NEC group) consisted of neonates whom were fed with a special rodent formula. Rats in groups 3 and 4 were fed in a similar fashion to those in group 2, and glutamine 0.3 mg/kg per day and dexamethasone 0.5 mg/kg per day were added to their formula, respectively. The neonatal rats were weighed and killed on day 4: the last 4 cm of terminal ileum was harvested for morphological studies and detection of nitrite and nitrate levels in tissue. The animals in the NEC group showed various degrees of inflammatory changes similar to clinical NEC. The inflammatory changes of the intestine appeared to be attenuated in both glutamine- and steroid-treated animals compared to those in the NEC group. Only steroid treatment decreased the tissue levels of these nitrogen oxides that were increased in rats in the NEC group. We herein provide evidence that maturational agents such as glutamine and dexametasone can attenuate the local intestinal inflammatory damage in experimental NEC. These findings support the hypothesis that the gut immaturity in premature infants represents a risk factor for NEC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dilsiz</LastName>
                    <ForeName>Alaeddin</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatric Surgery of Meram Medical Faculty, Sel√ßuk University, 42080 Konya, Turkey. dilsizdra@yahoo.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cift√ßi</LastName>
                    <ForeName>Ilhan</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aktan</LastName>
                    <ForeName>T Murad</ForeName>
                    <Initials>TM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>G√ºrbilek</LastName>
                    <ForeName>Mehmet</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karag√∂zoƒülu</LastName>
                    <ForeName>Emrah</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D023362">Evaluation Studies</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2003</Year>
                <Month>10</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Pediatr Surg Int</MedlineTA>
            <NlmUniqueID>8609169</NlmUniqueID>
            <ISSNLinking>0179-0358</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0RH81L854J</RegistryNumber>
                <NameOfSubstance UI="D005973">Glutamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>31C4KY9ESH</RegistryNumber>
                <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7S5I7G3JQL</RegistryNumber>
                <NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000596">Amino Acids</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000831">Animals, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003907">Dexamethasone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D019587">Dietary Supplements</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004750">Enteral Nutrition</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020345">Enterocolitis, Necrotizing</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005973">Glutamine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007413">Intestinal Mucosa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D023421">Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>10</Month>
                <Day>14</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2002</Year>
                <Month>Nov</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2003</Year>
                <Month>Oct</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>10</Month>
                <Day>14</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14556027</ArticleId>
            <ArticleId IdType="doi">10.1007/s00383-003-0980-y</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16872557</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>07</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>30</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0022-3573</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>58</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of pharmacy and pharmacology</Title>
                <ISOAbbreviation>J. Pharm. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of pancreatic lipase by poloxamer 407 may provide an adjunct treatment strategy for weight loss.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1099-105</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>This investigation was conducted to evaluate whether poloxamer 407 (P-407), a nonionic surface-active-agent that functions as a lipase inhibitor, could aid in weight loss by inactivating pancreatic lipase (PL) following oral administration to mice. Using a pH-titrimetric method, P-407 was evaluated for its ability to inhibit PL activity in-vitro. The palatability of drinking water containing P-407 (50 microM) was assessed in mice to determine whether inclusion of P-407 altered either the volume of water ingested, or the volume of urine produced, per day. P-407 at the same concentration was next evaluated for its potential to mediate weight loss over a one-month period in mice fed a high-fat diet. Faecal fat determinations and the potential for P-407 to lower plasma triacylglycerol concentrations following oral administration of a standard lipid emulsion were also conducted. P-407 was determined to have an IC50 of 15.9 microM in-vitro. Inclusion of P-407 in drinking water neither perturbed the daily volume of water ingested, nor the volume of urine produced. Over the course of one month, adult mice, which were fed the high-fat diet and treated with P-407, lost approximately 12.4+/-1.7% of their initial body weight, whereas, control mice fed the identical diet continued to slowly gain weight (7.3+/-0.5% of their initial body weight). The amount of total lipids excreted in the faeces of high-fat-fed, P-407-treated mice was approximately 45% greater than that observed for control mice eating the same diet. Lastly, plasma triacylglycerol concentrations following oral administration of the standard lipid emulsion containing P-407 were significantly lower than corresponding plasma triacylglycerol concentrations observed in mice administered the lipid emulsion alone. While not as potent as orlistat, P-407 may potentially represent an additional treatment strategy for weight loss, especially when combined with caloric restriction, regular exercise, and anti-obesity medications of other drug classes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Johnston</LastName>
                    <ForeName>Thomas P</ForeName>
                    <Initials>TP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pharmaceutical Science, School of Pharmacy, University of Missouri-Kansas City, 64110-2499, USA. johnstont@umkc.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goldberg</LastName>
                    <ForeName>Ira J</ForeName>
                    <Initials>IJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Pharm Pharmacol</MedlineTA>
            <NlmUniqueID>0376363</NlmUniqueID>
            <ISSNLinking>0022-3573</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005079">Excipients</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005217">Fat Emulsions, Intravenous</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005223">Fats</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>106392-12-5</RegistryNumber>
                <NameOfSubstance UI="D020442">Poloxamer</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.3</RegistryNumber>
                <NameOfSubstance UI="D008049">Lipase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005079">Excipients</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005217">Fat Emulsions, Intravenous</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005223">Fats</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005243">Feces</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008049">Lipase</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009765">Obesity</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010179">Pancreas</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020442">Poloxamer</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013649">Taste</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014280">Triglycerides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015431">Weight Loss</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>7</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>12</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>7</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1211/jpp.58.8.0011</ArticleId>
            <ArticleId IdType="pubmed">16872557</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21437948</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>05</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1554-527X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>29</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of orthopaedic research : official publication of the Orthopaedic Research Society</Title>
                <ISOAbbreviation>J. Orthop. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gait and behavior in an IL1Œ≤-mediated model of rat knee arthritis and effects of an IL1 antagonist.</ArticleTitle>
            <Pagination>
                <MedlinePgn>694-703</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jor.21309</ELocationID>
            <Abstract>
                <AbstractText>Interleukin-1 beta (IL1Œ≤) is a proinflammatory cytokine that mediates arthritic pathologies. Our objectives were to evaluate pain and limb dysfunction resulting from IL1Œ≤ over-expression in the rat knee and to investigate the ability of local IL1 receptor antagonist (IL1Ra) delivery to reverse-associated pathology. IL1Œ≤ over-expression was induced in the right knees of 30 Wistar rats via intra-articular injection of rat fibroblasts retrovirally infected with human IL1Œ≤ cDNA. A subset of animals received a 30‚Äâ¬µl intra-articular injection of saline or human IL1Ra on day 1 after cell delivery (0.65‚Äâ¬µg/¬µl hIL1Ra, n‚Äâ=‚Äâ7 per group). Joint swelling, gait, and sensitivity were investigated over 1 week. On day 8, animals were sacrificed and joints were collected for histological evaluation. Joint inflammation and elevated levels of endogenous IL1Œ≤ were observed in knees receiving IL1Œ≤-infected fibroblasts. Asymmetric gaits favoring the affected limb and heightened mechanical sensitivity (allodynia) reflected a unilateral pathology. Histopathology revealed cartilage loss on the femoral groove and condyle of affected joints. Intra-articular IL1Ra injection failed to restore gait and sensitivity to preoperative levels and did not reduce cartilage degeneration observed in histopathology. Joint swelling and degeneration subsequent to IL1Œ≤ over-expression is associated limb hypersensitivity and gait compensation. Intra-articular IL1Ra delivery did not result in marked improvement for this model; this may be driven by rapid clearance of administered IL1Ra from the joint space. These results motivate work to further investigate the behavioral consequences of monoarticular arthritis and sustained release drug delivery strategies for the joint space.</AbstractText>
                <CopyrightInformation>Copyright ¬© 2010 Orthopaedic Research Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Allen</LastName>
                    <ForeName>Kyle D</ForeName>
                    <Initials>KD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Orthopaedic Surgery, Duke University Medical Center, Duke University, Durham, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adams</LastName>
                    <ForeName>Samuel B</ForeName>
                    <Initials>SB</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mata</LastName>
                    <ForeName>Brian A</ForeName>
                    <Initials>BA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shamji</LastName>
                    <ForeName>Mohammed F</ForeName>
                    <Initials>MF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gouze</LastName>
                    <ForeName>Elvire</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jing</LastName>
                    <ForeName>Liufang</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nettles</LastName>
                    <ForeName>Dana L</ForeName>
                    <Initials>DL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Latt</LastName>
                    <ForeName>L Daniel</ForeName>
                    <Initials>LD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Setton</LastName>
                    <ForeName>Lori A</ForeName>
                    <Initials>LA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>F32 AR056190</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>F32 AR056190-01</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>F32AR056190</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K99 AR057426</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K99 AR057426-01</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K99 AR057426-02</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K99AR057426</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 AR050245</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 AR050245-09</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01AR050245</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R00 AR057426</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R00 AR057426-03</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R00 AR057426-04</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 EB002263</GrantID>
                    <Acronym>EB</Acronym>
                    <Agency>NIBIB NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 EB002263-07</GrantID>
                    <Acronym>EB</Acronym>
                    <Agency>NIBIB NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01EB002263</GrantID>
                    <Acronym>EB</Acronym>
                    <Agency>NIBIB NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21 AR052745</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21 AR052745-02</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21AR052745</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Orthop Res</MedlineTA>
            <NlmUniqueID>8404726</NlmUniqueID>
            <ISSNLinking>0736-0266</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 2007 Sep 24;571(1):8-16</RefSource>
                <PMID Version="1">17597604</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Vet Res. 2007 Mar;68(3):290-6</RefSource>
                <PMID Version="1">17331019</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BioDrugs. 2007;21(5):323-32</RefSource>
                <PMID Version="1">17896838</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2007 Nov;56(11):3650-61</RefSource>
                <PMID Version="1">17968946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biomech. 2008;41(2):276-83</RefSource>
                <PMID Version="1">18061197</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Res Ther. 2007;9(6):110</RefSource>
                <PMID Version="1">18086327</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pain. 2008 Oct;9(10):945-54</RefSource>
                <PMID Version="1">18650131</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Orthop Sci. 2008 Nov;13(6):514-23</RefSource>
                <PMID Version="1">19089539</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2009 Mar 15;61(3):344-52</RefSource>
                <PMID Version="1">19248129</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Musculoskelet Neuronal Interact. 2009 Apr-Jun;9(2):89-98</RefSource>
                <PMID Version="1">19516084</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Tissue Eng Part B Rev. 2010 Feb;16(1):81-92</RefSource>
                <PMID Version="1">19943805</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Vet Comp Orthop Traumatol. 2007;20(2):102-7</RefSource>
                <PMID Version="1">17546210</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Orthop Relat Res. 2001 Apr;(385):36-45</RefSource>
                <PMID Version="1">11302324</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Geriatr Nurs. 2001 May-Jun;22(3):124-30; quiz 130-1</RefSource>
                <PMID Version="1">11410762</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Osteoarthritis Cartilage. 2002 Oct;10(10):785-91</RefSource>
                <PMID Version="1">12359164</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Ther. 2003 Apr;7(4):460-6</RefSource>
                <PMID Version="1">12727108</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Neurol. 2003 Oct;183(2):695-9</RefSource>
                <PMID Version="1">14552911</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Physiotherapy. 1980 Aug;66(8):271-3</RefSource>
                <PMID Version="1">6450426</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol. 1988 Dec;15(12):1841-7</RefSource>
                <PMID Version="1">3265960</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol. 1990 Dec;17(12):1662-9</RefSource>
                <PMID Version="1">2084242</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1991 Apr 15;77(8):1627-52</RefSource>
                <PMID Version="1">1826616</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 1991 Dec;34(12):1560-70</RefSource>
                <PMID Version="1">1747141</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 1992 Oct;35(10):1150-9</RefSource>
                <PMID Version="1">1329773</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cytokine. 1992 Sep;4(5):353-60</RefSource>
                <PMID Version="1">1420996</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Arthritis Rheum. 1993 Jun;22(6 Suppl 1):18-30</RefSource>
                <PMID Version="1">8342050</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 1993 Nov;36(11):1517-27</RefSource>
                <PMID Version="1">8240429</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci Methods. 1994 Jul;53(1):55-63</RefSource>
                <PMID Version="1">7990513</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 1995 Feb;38(2):164-72</RefSource>
                <PMID Version="1">7848306</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 1996 Sep;39(9):1535-44</RefSource>
                <PMID Version="1">8814066</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol. 1997 Feb;24(2):365-71</RefSource>
                <PMID Version="1">9034998</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 1997 Jun;40(6):1012-9</RefSource>
                <PMID Version="1">9182910</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1997 Oct 1;159(7):3604-12</RefSource>
                <PMID Version="1">9317160</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Physiol Behav. 1997 Nov;62(5):951-4</RefSource>
                <PMID Version="1">9333186</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Assoc Am Physicians. 1998 Jan-Feb;110(1):65-72</RefSource>
                <PMID Version="1">9460084</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol. 1998 Dec;25(12):2417-24</RefSource>
                <PMID Version="1">9858439</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann N Y Acad Sci. 1998 Sep 29;856:1-11</RefSource>
                <PMID Version="1">9917859</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gene Ther. 1999 Oct;6(10):1713-20</RefSource>
                <PMID Version="1">10516720</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1999 Nov 1;163(9):5049-55</RefSource>
                <PMID Version="1">10528210</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gene Ther. 2005 Jan;12(2):177-86</RefSource>
                <PMID Version="1">15578043</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol. 2005 Jul;32(7):1317-23</RefSource>
                <PMID Version="1">15996071</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2006 Jan;54(1):226-9</RefSource>
                <PMID Version="1">16385518</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Osteoarthritis Cartilage. 2006 Jan;14(1):13-29</RefSource>
                <PMID Version="1">16242352</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pain. 2006 Jul;123(1-2):98-105</RefSource>
                <PMID Version="1">16564620</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Osteoarthritis Cartilage. 2006 Oct;14(10):1041-8</RefSource>
                <PMID Version="1">16769229</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Histopathology. 2006 Oct;49(4):358-64</RefSource>
                <PMID Version="1">16978198</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Control Release. 2006 Oct 10;115(2):175-82</RefSource>
                <PMID Version="1">16959360</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 2007 Oct;66(10):1271-5</RefSource>
                <PMID Version="1">17267516</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001168">Arthritis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D001522">Behavior, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D005684">Gait</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006614">Hindlimb</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007270">Injections, Intra-Articular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053590">Interleukin 1 Receptor Antagonist Protein</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053583">Interleukin-1beta</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007596">Joints</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS292244</OtherID>
        <OtherID Source="NLM">PMC3100769</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jor.21309</ArticleId>
            <ArticleId IdType="pubmed">21437948</ArticleId>
            <ArticleId IdType="pmc">PMC3100769</ArticleId>
            <ArticleId IdType="mid">NIHMS292244</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20037105</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>10</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1522-6662</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>12</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The heart surgery forum</Title>
                <ISOAbbreviation>Heart Surg Forum</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Heparin-induced thrombosis without thrombocytopenia causing fulminant pulmonary embolism after off-pump coronary artery bypass grafting.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E368-70</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1532/HSF98.20091057</ELocationID>
            <Abstract>
                <AbstractText>Heparin-induced thrombocytopenia (HIT) is a rare immune-mediated complication of heparin administration. A potentially life-threatening complication, HIT is difficult to diagnose in patients in the intensive care unit after cardiac surgery because there can be multiple reasons for thrombocytopenia. Moreover, immune-mediated platelet consumption may be masked by reactive thrombocytosis, which is common in the typical postoperative course after cardiac surgery. We report the case of a 57-year-old male patient who developed fulminant pulmonary embolism following heparin-induced thrombosis without thrombocytopenia after off-pump coronary artery bypass surgery.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bigdeli</LastName>
                    <ForeName>Amir K</ForeName>
                    <Initials>AK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiac Surgery, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistr. 15, D-81377 M√ºnchen, Germany. Amir_Khosrow.Bigdeli@med.uni-muenchen.de</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmitz</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bruegger</LastName>
                    <ForeName>Dirk</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weis</LastName>
                    <ForeName>Florian</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weis</LastName>
                    <ForeName>Marion</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michel</LastName>
                    <ForeName>Sebastian</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmauss</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reichart</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reichart</LastName>
                    <ForeName>Bruno</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sodian</LastName>
                    <ForeName>Ralf</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Heart Surg Forum</MedlineTA>
            <NlmUniqueID>100891112</NlmUniqueID>
            <ISSNLinking>1098-3511</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9005-49-6</RegistryNumber>
                <NameOfSubstance UI="D006493">Heparin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D047549">Coronary Artery Bypass, Off-Pump</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006331">Heart Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006493">Heparin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011655">Pulmonary Embolism</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013921">Thrombocytopenia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013927">Thrombosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">97K45N1G5T006358</ArticleId>
            <ArticleId IdType="doi">10.1532/HSF98.20091057</ArticleId>
            <ArticleId IdType="pubmed">20037105</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15148266</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>06</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>01</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0007-1188</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>142</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of pharmacology</Title>
                <ISOAbbreviation>Br. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>543-50</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>1 Stress is a risk factor in psychiatric illnesses such as schizophrenia. The aim of the present study was to investigate the effect of different circulating levels of the adrenal steroid corticosterone (CORT) on locomotor hyperactivity and prepulse inhibition of acoustic startle, two behavioural animal models of aspects of schizophrenia. 2 Male C57BL/6J mice (n=10 per group) were anaesthetised with isoflurane and sham-operated or adrenalectomised (ADX). ADX mice were implanted with 50 mg pellets consisting of 100% cholesterol, or 2, 10 or 50 mg of CORT mixed with cholesterol. CORT pellet implantation dose dependently increased plasma CORT levels 3 weeks after surgery. Starting 1 week after surgery, mice were tested for prepulse inhibition after injection of saline or 5 mg kg(-1) of haloperidol. 3 In intact mice and in mice implanted with 10 mg of CORT, haloperidol treatment significantly increased prepulse inhibition (average values from 38 - 42 to 52%). Similar results were observed when testing the mice for amphetamine-induced locomotor hyperactivity (5 mg kg(-1)). In contrast, there was no significant effect of haloperidol in mice implanted either with cholesterol or 2 or 50 mg of CORT. 4 These results in behavioural animal models of schizophrenia suggest an important role of the stress hormone CORT in modulating dopaminergic activity in this illness.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van den Buuse</LastName>
                    <ForeName>Maarten</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Behavioural Neuroscience Laboratory, Mental Health Research Institute of Victoria, 155 Oak Street, Parkville, Victoria 3052, Australia. mvandenbuuse@mhri.edu.au</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morris</LastName>
                    <ForeName>Margaret</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chavez</LastName>
                    <ForeName>Carolina</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>Sally</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>JianHong</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2004</Year>
                <Month>05</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Pharmacol</MedlineTA>
            <NlmUniqueID>7502536</NlmUniqueID>
            <ISSNLinking>0007-1188</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>CK833KGX7E</RegistryNumber>
                <NameOfSubstance UI="D000661">Amphetamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J6292F8L3D</RegistryNumber>
                <NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>W980KJ009P</RegistryNumber>
                <NameOfSubstance UI="D003345">Corticosterone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 1999 Nov;147(1):11-3</RefSource>
                <PMID Version="1">10591857</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prog Neurobiol. 1999 Oct;59(2):107-28</RefSource>
                <PMID Version="1">10463792</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Neurosci. 2000 Mar;12(3):973-9</RefSource>
                <PMID Version="1">10762327</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Gen Psychiatry. 2000 Jun;57(6):609-14</RefSource>
                <PMID Version="1">10839340</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 2000 Sep 29;405(1-3):375-84</RefSource>
                <PMID Version="1">11033342</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Psychiatry. 2001 Jan 15;49(2):81-96</RefSource>
                <PMID Version="1">11164755</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):679-85</RefSource>
                <PMID Version="1">11401919</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 2001 Jul 13;424(1):27-36</RefSource>
                <PMID Version="1">11470257</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):359-66</RefSource>
                <PMID Version="1">11509192</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Psychopathol. 2001 Summer;13(3):565-80</RefSource>
                <PMID Version="1">11523848</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 2001 Jul;156(2-3):273-83</RefSource>
                <PMID Version="1">11549229</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Physiol Behav. 2002 Feb 1-15;75(1-2):207-15</RefSource>
                <PMID Version="1">11890970</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 2002 May;161(3):296-303</RefSource>
                <PMID Version="1">12021833</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Life Sci. 2002 Nov 29;72(2):163-71</RefSource>
                <PMID Version="1">12417250</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neuroendocrinol. 2002 Nov;14(11):880-6</RefSource>
                <PMID Version="1">12421341</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2002 Dec;143(12):4520-6</RefSource>
                <PMID Version="1">12446578</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Psychiatry. 2002;7(10):1039-53</RefSource>
                <PMID Version="1">12476318</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropsychopharmacology. 2003 Oct;28(10):1790-8</RefSource>
                <PMID Version="1">12865891</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res. 1975 Jan 17;83(3):419-36</RefSource>
                <PMID Version="1">234270</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res. 1975 Sep 5;94(3):507-22</RefSource>
                <PMID Version="1">1171714</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Comp Physiol Psychol. 1979 Aug;93(4):745-51</RefSource>
                <PMID Version="1">479406</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 1985 Dec;117(6):2505-11</RefSource>
                <PMID Version="1">2998738</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Steroid Biochem. 1986 Jan;24(1):269-72</RefSource>
                <PMID Version="1">3702410</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1986 Aug;238(2):693-700</RefSource>
                <PMID Version="1">2874216</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann N Y Acad Sci. 1988;537:138-47</RefSource>
                <PMID Version="1">3059920</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Gen Psychiatry. 1990 Feb;47(2):181-8</RefSource>
                <PMID Version="1">2405807</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 1990;100(3):413-6</RefSource>
                <PMID Version="1">2315438</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroendocrinology. 1992 Apr;55(4):468-76</RefSource>
                <PMID Version="1">1314340</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Gen Psychiatry. 1992 Mar;49(3):206-15</RefSource>
                <PMID Version="1">1567275</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroscience. 1993 Oct;56(4):981-8</RefSource>
                <PMID Version="1">8284048</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Psychiatr Scand Suppl. 1994;382:58-64</RefSource>
                <PMID Version="1">8091999</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci. 1995 Nov;15(11):7181-8</RefSource>
                <PMID Version="1">7472472</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Pharmacol Toxicol. 1996;36:359-78</RefSource>
                <PMID Version="1">8725394</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9235-40</RefSource>
                <PMID Version="1">8799184</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chin J Physiol. 1996;39(3):139-46</RefSource>
                <PMID Version="1">8955560</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15445-50</RefSource>
                <PMID Version="1">8986831</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Psychiatr Res. 1997 Mar-Apr;31(2):257-75</RefSource>
                <PMID Version="1">9278189</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychol Rev. 1997 Oct;104(4):667-85</RefSource>
                <PMID Version="1">9337628</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Neurosci. 1997 Dec;111(6):1353-60</RefSource>
                <PMID Version="1">9438803</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroscience. 1998 Jan;82(2):521-8</RefSource>
                <PMID Version="1">9466458</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res Brain Res Rev. 1997 Dec;25(3):359-72</RefSource>
                <PMID Version="1">9495563</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Schizophr Bull. 1998;24(2):285-301</RefSource>
                <PMID Version="1">9613626</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocr Rev. 1998 Jun;19(3):269-301</RefSource>
                <PMID Version="1">9626555</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 1999 Jan;140(1):310-7</RefSource>
                <PMID Version="1">9886840</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci. 1999 Jun 1;19(11):4627-33</RefSource>
                <PMID Version="1">10341260</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropsychopharmacology. 1999 Sep;21(3):399-407</RefSource>
                <PMID Version="1">10457537</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Psychiatry. 2000 Jan;5(1):14-21</RefSource>
                <PMID Version="1">10673764</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D000315">Adrenalectomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000661">Amphetamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003345">Corticosterone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006220">Haloperidol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009433">Neural Inhibition</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013216">Reflex, Startle</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1574955</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>1</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15148266</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.bjp.0705511</ArticleId>
            <ArticleId IdType="pii">0705511</ArticleId>
            <ArticleId IdType="pmc">PMC1574955</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15148268</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>06</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4539</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>109</Volume>
                    <Issue>22</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Jun</Month>
                        <Day>8</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Circulation</Title>
                <ISOAbbreviation>Circulation</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2773-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Carvedilol is a beta-adrenoceptor blocker with a vasodilatory action that is more effective for the treatment of congestive heart failure than other beta-blockers. Recently, carvedilol has been reported to reduce oxidative stress, which may consequently reduce the deactivation of adenosine-producing enzymes and increase cardiac adenosine levels. Therefore, carvedilol may also have a protective effect on ischemia and reperfusion injury, because adenosine mediates cardioprotection in ischemic hearts.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">In anesthetized dogs, the left anterior descending coronary artery was occluded for 90 minutes, followed by reperfusion for 6 hours. Carvedilol reduced the infarct size (15.0+/-2.8% versus 40.9+/-4.2% in controls), and this effect was completely reversed by the nonselective adenosine receptor antagonist 8-sulfophenyltheophylline (45.2+/-5.4%) or by an inhibitor of ecto-5'-nucleotidase (44.4+/-3.6%). There were no differences of either area at risk or collateral flow among the various groups. When the coronary perfusion pressure was reduced in other dogs so that coronary blood flow was decreased to 50% of the nonischemic level, carvedilol increased coronary blood flow (49.4+/-5.6 to 73.5+/-7.5 mL x 100 g(-1) x min(-1); P&lt;0.05) and adenosine release (112.3+/-22.2 to 240.6+/-57.1 nmol/L; P&lt;0.05) during coronary hypoperfusion. This increase of coronary blood flow was attenuated by either 8-sulfophenyltheophylline or superoxide dismutase. In human umbilical vein endothelial cells cultured with or without xanthine and xanthine oxidase, carvedilol caused an increase of ecto-5'-nucleotidase activity.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Carvedilol shows a cardioprotective effect against ischemia and/or reperfusion injury via adenosine-dependent mechanisms.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Asanuma</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Minamino</LastName>
                    <ForeName>Tetsuo</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanada</LastName>
                    <ForeName>Shoji</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takashima</LastName>
                    <ForeName>Seiji</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogita</LastName>
                    <ForeName>Hisakazu</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogai</LastName>
                    <ForeName>Akiko</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asakura</LastName>
                    <ForeName>Masanori</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liao</LastName>
                    <ForeName>Yulin</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asano</LastName>
                    <ForeName>Yoshihiro</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shintani</LastName>
                    <ForeName>Yasunori</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Jiyoong</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shinozaki</LastName>
                    <ForeName>Yoshiro</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mori</LastName>
                    <ForeName>Hidezo</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Node</LastName>
                    <ForeName>Koichi</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitamura</LastName>
                    <ForeName>Soichiro</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomoike</LastName>
                    <ForeName>Hitonobu</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hori</LastName>
                    <ForeName>Masatsugu</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitakaze</LastName>
                    <ForeName>Masafumi</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2004</Year>
                <Month>05</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Circulation</MedlineTA>
            <NlmUniqueID>0147763</NlmUniqueID>
            <ISSNLinking>0009-7322</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002227">Carbazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011412">Propanolamines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0K47UL67F2</RegistryNumber>
                <NameOfSubstance UI="C043211">carvedilol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9Y8NXQ24VQ</RegistryNumber>
                <NameOfSubstance UI="D011433">Propranolol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.5</RegistryNumber>
                <NameOfSubstance UI="D015720">5'-Nucleotidase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>K72T3FS567</RegistryNumber>
                <NameOfSubstance UI="D000241">Adenosine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015720">5'-Nucleotidase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000241">Adenosine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000319">Adrenergic beta-Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002227">Carbazoles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003326">Coronary Circulation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009203">Myocardial Infarction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017202">Myocardial Ischemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009206">Myocardium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011412">Propanolamines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011433">Propranolol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2004</Year>
                <Month>May</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15148268</ArticleId>
            <ArticleId IdType="doi">10.1161/01.CIR.0000130917.12959.04</ArticleId>
            <ArticleId IdType="pii">01.CIR.0000130917.12959.04</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">623348</PMID>
        <DateCreated>
            <Year>1978</Year>
            <Month>03</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1978</Year>
            <Month>03</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-953X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>135</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1978</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of psychiatry</Title>
                <ISOAbbreviation>Am J Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Methylphenidate-induced choreoathetosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>252-3</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Extein</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Psychiatry</MedlineTA>
            <NlmUniqueID>0370512</NlmUniqueID>
            <ISSNLinking>0002-953X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>207ZZ9QZ49</RegistryNumber>
                <NameOfSubstance UI="D008774">Methylphenidate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9U1VM840SP</RegistryNumber>
                <NameOfSubstance UI="D010830">Physostigmine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>A01LX40298</RegistryNumber>
                <NameOfSubstance UI="D008701">Methapyrilene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J6292F8L3D</RegistryNumber>
                <NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006220">Haloperidol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008701">Methapyrilene</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008774">Methylphenidate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010830">Physostigmine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011954">Receptors, Dopamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1978</Year>
                <Month>2</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1978</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1978</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">623348</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">4006743</PMID>
        <DateCreated>
            <Year>1985</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1985</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0012-6578</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1985</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Drug intelligence &amp; clinical pharmacy</Title>
                <ISOAbbreviation>Drug Intell Clin Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tolmetin-induced urticaria/angioedema.</ArticleTitle>
            <Pagination>
                <MedlinePgn>479-80</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ponte</LastName>
                    <ForeName>C D</ForeName>
                    <Initials>CD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wisman</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Drug Intell Clin Pharm</MedlineTA>
            <NlmUniqueID>0212457</NlmUniqueID>
            <ISSNLinking>0012-6578</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>D8K2JPN18B</RegistryNumber>
                <NameOfSubstance UI="D014046">Tolmetin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000799">Angioedema</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011758">Pyrroles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014046">Tolmetin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014581">Urticaria</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1985</Year>
                <Month>6</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1985</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1985</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4006743</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">481577</PMID>
        <DateCreated>
            <Year>1979</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1979</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0083-1921</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Issue>51</Issue>
                    <PubDate>
                        <Year>1979</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>National Cancer Institute monograph</Title>
                <ISOAbbreviation>Natl Cancer Inst Monogr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prenatal diethylstilbestrol exposure and human genital tract abnormalities.</ArticleTitle>
            <Pagination>
                <MedlinePgn>25-35</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The incidence of clear cell adenocarcinoma of the vagina and cervix associated with intrauterine exposure to DES and similar compounds during the first half of pregnancy has increased. Ninety percent of these cancers have occurred in patients 14 years of age or older. Although these carcinomas are exceedingly rare, nonneoplastic abnormalities including vaginal adenosis, cervical eversion (ectropion), and transverse cervical and vaginal ridges are frequent in the exposed population, particularly if the drug was administered early in pregnancy. Current evidence favors a disturbance in development of the m√ºllerian duct as the explanation of these changes. Whether DES is only a teratogen or also a carcinogen is unknown, as is the possible role of other factors in the development of cancer. An increased incidence of cancer among exposed males has not been documented.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Herbst</LastName>
                    <ForeName>A L</ForeName>
                    <Initials>AL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scully</LastName>
                    <ForeName>R E</ForeName>
                    <Initials>RE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robboy</LastName>
                    <ForeName>S J</ForeName>
                    <Initials>SJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Natl Cancer Inst Monogr</MedlineTA>
            <NlmUniqueID>0216026</NlmUniqueID>
            <ISSNLinking>0083-1921</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>731DCA35BT</RegistryNumber>
                <NameOfSubstance UI="D004054">Diethylstilbestrol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000196">embryology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002584">Cervix Uteri</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000002">abnormalities</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004054">Diethylstilbestrol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004812">Epidemiologic Methods</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005865">Gestational Age</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D008431">Maternal-Fetal Exchange</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008679">Metaplasia</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002583">Uterine Cervical Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000196">embryology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014621">Vagina</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000002">abnormalities</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014625">Vaginal Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000196">embryology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1979</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1979</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1979</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">481577</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12166551</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>08</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>09</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2007</Year>
            <Month>02</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1368-5031</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>56</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <MedlineDate>2002 Jul-Aug</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of clinical practice</Title>
                <ISOAbbreviation>Int. J. Clin. Pract.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Upper airway obstruction and acute lung injury associated with cocaine abuse.</ArticleTitle>
            <Pagination>
                <MedlinePgn>484-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We describe the case of a 14-year-old boy who developed airway obstruction due to acute upper respiratory tract infection. Following emergency tracheostomy, he developed pulmonary oedema and required ventilation. The postoperative course was complicated by the development of adult respiratory distress syndrome, characterised by marked respiratory distress, diffuse pulmonary infiltrates on chest radiography, reduced pulmonary compliance and marked increase in alveolar-arterial oxygen difference. He also developed persistent high-grade pyrexia, renal failure and cardiac instability. A social history of substance abuse (crack cocaine, amphetamines, alcohol and cigarettes) was obtained three weeks post-admission and is thought to have made a significant contribution to the severity of his disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ali</LastName>
                    <ForeName>S Raza</ForeName>
                    <Initials>SR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Royal Gwent Hospital, Newport, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krugar</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Houghton</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Int J Clin Pract</MedlineTA>
            <NlmUniqueID>9712381</NlmUniqueID>
            <ISSNLinking>1368-5031</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016578">Crack Cocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000402">Airway Obstruction</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000428">Alcohol Drinking</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019969">Amphetamine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D016578">Crack Cocaine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011654">Pulmonary Edema</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012907">Smoking</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>8</Month>
                <Day>9</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>28</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>8</Month>
                <Day>9</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12166551</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22060784</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>01</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>05</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-5118</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>59</Volume>
                    <Issue>24</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Dec</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of agricultural and food chemistry</Title>
                <ISOAbbreviation>J. Agric. Food Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Soyasaponin Ab ameliorates colitis by inhibiting the binding of lipopolysaccharide (LPS) to Toll-like receptor (TLR)4 on macrophages.</ArticleTitle>
            <Pagination>
                <MedlinePgn>13165-72</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1021/jf2033818</ELocationID>
            <Abstract>
                <AbstractText>Many clinical studies have shown that daily intake of soybean [ Glycine max (L.) Merr., Fabacease] or its foods may reduce the risk of osteoporosis, heart attack, hyperlipidemia, coronary heart disease, cardiovascular and chronic renal diseases, and cancers, including prostate, colon, and breast cancers. Of the soy constituents, soyasaponins exhibit anti-aging, antioxidant, apoptotic, and anti-inflammatory effects. However, the anti-inflammatory effect of soyasaponin Ab has not been thoroughly studied. Therefore, we investigated its anti-inflammatory effects in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitic mice and lipopolysaccharide (LPS)-stimulated peritoneal macrophages. Soyasaponin Ab inhibited colon shortening, myeloperoxidase activity, the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and activation of the transcription factor nuclear factor-Œ∫B (NF-Œ∫B). Soyasaponin Ab (1, 2, 5, and 10 ŒºM) inhibited the production of NO (IC(50) = 1.6 ¬± 0.1 ŒºM) and prostaglandin E(2) (IC(50) = 2.0 ¬± 0.1 ng/mL), the expression of tumor necrosis factor (TNF)-Œ± (IC(50) = 1.3 ¬± 0.1 ng/mL), interleukin (IL)-1Œ≤ (IC(50) = 1.5 ¬± 0.1 pg/mL), and toll-like receptor (TLR)4, and the phosphorylation of interleukin-1 receptor-associated kinase (IRAK)-1 in LPS-stimulated peritoneal macrophages. Soyasaponin Ab weakly inhibited the phosphorylation of ERK, JNK, and p38. Soyasaponin Ab significantly reduced the binding of Alexa-Fluor-594-conjugated LPS to peritoneal macrophages. Soyasaponin Ab did not affect TLR4 expression or LPS-induced NF-Œ∫B activation in TLR4 siRNA-treated peritoneal macrophages (knockdown efficiency of TLR4 &gt; 94%). On the basis of these findings, soyasaponin Ab may ameliorate colitis by inhibiting the binding of LPS to TLR4 on macrophages.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>In-Ah</ForeName>
                    <Initials>IA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Life and Nanopharmaceutical Sciences, College of Pharmacy, Kyung Hee University, 1 Hoegi, Dongdaemun-gu, Seoul 130-701, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Young-Jun</ForeName>
                    <Initials>YJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Joh</LastName>
                    <ForeName>Eun-Ha</ForeName>
                    <Initials>EH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Dong-Hyun</ForeName>
                    <Initials>DH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Agric Food Chem</MedlineTA>
            <NlmUniqueID>0374755</NlmUniqueID>
            <ISSNLinking>0021-8561</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012503">Saponins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C493487">Tlr4 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C551307">soyasaponin Ab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8T3HQG2ZC4</RegistryNumber>
                <NameOfSubstance UI="D014302">Trinitrobenzenesulfonic Acid</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003092">Colitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017737">Macrophages, Peritoneal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008813">Mice, Inbred ICR</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012503">Saponins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051197">Toll-Like Receptor 4</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014302">Trinitrobenzenesulfonic Acid</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jf2033818</ArticleId>
            <ArticleId IdType="pubmed">22060784</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25451575</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>12</Month>
            <Day>2</Day>
        </DateCreated>
        <DateRevised>
            <Year>2014</Year>
            <Month>12</Month>
            <Day>3</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7786</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>224C</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chemico-biological interactions</Title>
                <ISOAbbreviation>Chem. Biol. Interact.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-inflammatory effects of 7-hydroxyl-1-methylindole-3-acetonitrile, a synthetic arvelexin derivative, on the macrophages through destabilizing mPGES-1 mRNA and suppressing NF-Œ∫B activation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>68-77</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S0009-2797(14)00292-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.cbi.2014.10.004</ELocationID>
            <Abstract>
                <AbstractText>We previously demonstrated that 7-hydroxyl-1-methylindole-3-acetonitrile (7-HMIA), a synthesized analog of arvelexin, showed the strong inhibitory effects on LPS-induced NO and PGE2 production in macrophages. In this study, we focused on elucidating the anti-inflammatory properties of 7-HMIA and the mechanisms involved using in vitro and in vivo experimental models. In LPS-induced RAW 264.7 macrophages, 7-HMIA significantly inhibited the release of proinflammatory mediators such as prostaglandin E2 (PGE2), nitric oxide (NO), tumor necrosis factor-Œ± (TNF-Œ±), and interleukin-6 (IL-6). We also found that 7-HMIA suppressed PGE2 production not by inhibiting cyclooxygenase-2 (COX-2) expression or activity, but rather by suppressing the mRNA stability of microsomal prostaglandin E synthase (mPGES-1). Furthermore, 7-HMIA mediated attenuation of inducible NO synthase (iNOS), TNF-Œ±, and IL-6 was closely associated with suppression of transcriptional activities of nuclear factor-kappa B (NF-Œ∫B), by decreasing p65 nuclear translocation and Akt phosphorylation. Animal studies revealed that 7-HMIA potently suppressed the carrageenan-induced paw edema and myeloperoxidase (MPO) activity in paw tissues. Taken together, our data indicated that the molecular basis for the anti-inflammatory properties of 7-HMIA involved the inhibition of mRNA stability of mPGES-1 and PI3K/Akt-mediated NF-Œ∫B pathways.</AbstractText>
                <CopyrightInformation>Copyright ¬© 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Shin</LastName>
                    <ForeName>Ji-Sun</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea; Reactive Oxygen Species Medical Research Center, School of Medicine, Kyung Hee University, Seoul, Republic of Korea; Department of Physiology, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Choi</LastName>
                    <ForeName>Hye-Eun</ForeName>
                    <Initials>HE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea; Department of Life and Nanopharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Soo-Dong</ForeName>
                    <Initials>SD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, College of Medicine, Dong-A University, Pusan 602-715, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Yong Sup</ForeName>
                    <Initials>YS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Life and Nanopharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea; Laboratory of Medicinal Chemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Cho</LastName>
                    <ForeName>Young-Wuk</ForeName>
                    <Initials>YW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Reactive Oxygen Species Medical Research Center, School of Medicine, Kyung Hee University, Seoul, Republic of Korea; Department of Physiology, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Kyung Tae</ForeName>
                    <Initials>KT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea; Department of Life and Nanopharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea. Electronic address: ktlee@khu.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType UI="">JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Chem Biol Interact</MedlineTA>
            <NlmUniqueID>0227276</NlmUniqueID>
            <ISSNLinking>0009-2797</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">7-Hydroxyl-1-methylindole-3-acetonitrile</Keyword>
            <Keyword MajorTopicYN="N">Inflammatory mediator</Keyword>
            <Keyword MajorTopicYN="N">Microsomal prostaglandin E synthase</Keyword>
            <Keyword MajorTopicYN="N">Nuclear factor-kappa B</Keyword>
            <Keyword MajorTopicYN="N">mRNA stability</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25451575</ArticleId>
            <ArticleId IdType="pii">S0009-2797(14)00292-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cbi.2014.10.004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9640485</PMID>
        <DateCreated>
            <Year>1998</Year>
            <Month>09</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1998</Year>
            <Month>09</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1060-0280</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>32</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1998</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Annals of pharmacotherapy</Title>
                <ISOAbbreviation>Ann Pharmacother</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Probable diltiazem-induced acute interstitial nephritis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>656-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe a case of acute interstitial nephritis (AIN) probably related to administration of diltiazem.</AbstractText>
                <AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 53-year-old white man presented to the hospital experiencing abdominal pain radiating to both renal fossae, as well as dysuria. Diltiazem and atenolol had been prescribed to treat an episode of precordial pain associated with effort. An erythematous maculopapular rash developed approximately 2 hours after administration of a single dose of diltiazem, and acute renal failure, associated with elevated liver function test results, developed 6 days later.</AbstractText>
                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">To the best of our knowledge, this is the third reported case of acute renal failure believed to be induced by diltiazem. In all cases, there was an obvious temporal relationship between administration of diltiazem and the onset of acute renal failure. Previous reports failed to discuss a probable pathogenic mechanism. AIN is the most likely etiology of acute renal failure in our patient. Favorable resolution with no relapse, the presence of the skin rash, and the liver sequelae suggest a common immunoallergic mechanism.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Healthcare professionals should consider diltiazem-induced AIN in the differential diagnosis of a patient taking diltiazem who develops acute renal failure.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Abad√≠n</LastName>
                    <ForeName>J A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, Faculty of Medicine, University Hospital Virgen Macarena, Seville, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dur√°n</LastName>
                    <ForeName>J A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>P√©rez de Le√≥n</LastName>
                    <ForeName>J A</ForeName>
                    <Initials>JA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Ann Pharmacother</MedlineTA>
            <NlmUniqueID>9203131</NlmUniqueID>
            <ISSNLinking>1060-0280</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EE92BBP03H</RegistryNumber>
                <NameOfSubstance UI="D004110">Diltiazem</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002121">Calcium Channel Blockers</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003327">Coronary Disease</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004110">Diltiazem</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009395">Nephritis, Interstitial</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1998</Year>
                <Month>6</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1998</Year>
                <Month>6</Month>
                <Day>26</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1998</Year>
                <Month>6</Month>
                <Day>26</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9640485</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2214444</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0021-5252</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>43</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Kyobu geka. The Japanese journal of thoracic surgery</Title>
                <ISOAbbreviation>Kyobu Geka</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Right ventricular thrombosis due to familial heparin cofactor II deficiency].</ArticleTitle>
            <Pagination>
                <MedlinePgn>830-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>This case report was with regard to familial heparin cofactor II (HC II) deficiency. The patient was a 14-years-old female, having complaints of chest pain, fever and swelling of right lower extremity. Echocardiography and DSA showed a pediculated mass at the right ventricular outflow tract which highly suggested a ventricular myxoma. At surgery, a large pediculated thrombus was removed from the RV conus septum aun pulmonary valve. The mass was identified as thrombus by histological examination. Two months later, the RV thrombi recurred with additional pulmonary embolus to the left lung. HC II was discovered by hemo-coagulation tests. Her HC II antigen value was 48%, and 32% on repeat study. Her brother's HC II antigen value was 53%. At reoperation, small thrombi less than phi 10 mm, were removed from the RV outflow tract and pulmonary valve. Fresh frozen plasma was given and intravenous urokinase therapy was taken. She is doing well with therapy of oral warfarin, aspirin and ticlopidine for anticoagulation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nagae</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Second Department of Surgery, Yamagata University School of Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watanabe</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miura</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Minowa</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirooka</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Washio</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>jpn</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>JAPAN</Country>
            <MedlineTA>Kyobu Geka</MedlineTA>
            <NlmUniqueID>0413533</NlmUniqueID>
            <ISSNLinking>0021-5252</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>81604-65-1</RegistryNumber>
                <NameOfSubstance UI="D015844">Heparin Cofactor II</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006331">Heart Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006352">Heart Ventricles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015844">Heparin Cofactor II</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012086">Reoperation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013927">Thrombosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>13</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>9</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2214444</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12465085</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>03</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0885-3185</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Movement disorders : official journal of the Movement Disorder Society</Title>
                <ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clozapine withdrawal symptoms in a Parkinson's disease patient.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1365-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Abrupt clozapine withdrawal can cause rebound psychosis and severe somatic symptoms in psychiatric patients. We report on the case of an advanced Parkinson's disease patient who developed myoclonus, tremor, rigidity, hyperreflexia, and stupor after abrupt clozapine withdrawal. The patient's symptoms resolved with treatment with cyproheptadine. This clinical picture suggests serotonergic rebound as an explanation for the patient's symptoms, although other pharmacological mechanisms are possible. Clozapine should be gradually withdrawn over a period of 1 to 2 weeks when possible, and abruptly discontinued only when necessary.</AbstractText>
                <CopyrightInformation>Copyright 2002 Movement Disorder Society</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zesiewicz</LastName>
                    <ForeName>Theresa A</ForeName>
                    <Initials>TA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Parkinson's Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA. tzesiewi@hsc.usf.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borra</LastName>
                    <ForeName>Sujatha</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hauser</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mov Disord</MedlineTA>
            <NlmUniqueID>8610688</NlmUniqueID>
            <ISSNLinking>0885-3185</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C009265">carbidopa, levodopa drug combination</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>46627O600J</RegistryNumber>
                <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J60AR2IKIC</RegistryNumber>
                <NameOfSubstance UI="D003024">Clozapine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MNX7R8C5VO</RegistryNumber>
                <NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002230">Carbidopa</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003024">Clozapine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006212">Hallucinations</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013375">Substance Withdrawal Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12465085</ArticleId>
            <ArticleId IdType="doi">10.1002/mds.10282</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12215948</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>09</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>01</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0044-2771</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>40</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Zeitschrift f√ºr Gastroenterologie</Title>
                <ISOAbbreviation>Z Gastroenterol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.</ArticleTitle>
            <Pagination>
                <MedlinePgn>795-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Survival rates of hepatitis B patients after liver transplantation improved significantly by introduction of passive immunoprophylaxis. Due to viral escape mutations recurrence still occurs, but recently a combination prophylaxis with hepatitis B immunoglobuline plus lamivudine is evaluated in transplant centers in terms of a further reduction of recurrence rates.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Between 1996 and 2000 a postoperative combination prophylaxis with HBIg and lamivudine was initiated in 44 HBsAg positive liver transplant recipients. In total 14 patients were HBV-DNA negative and 30 were HBV-DNA positive at the time of evaluation. In 22 HBV-DNA positive patients a pre-operative lamivudine treatment (150 mg/die) was started. Five of them developed pre-transplant lamivudine resistance with high viral replication (mean HBV-DNA prior to transplantation 728 +/- 219 pg/ml). In all patients passive immunoprophylaxis was started in the anhepatic phase with application of 10.000 units hepatitis B immunoglobuline. It was continued after seroconversion to HBsAg negativity with an aimed titer of more than 100 U/l and only stopped in case of HBV recurrence. Lamivudine was also continued indefinitely after liver transplantation.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall recurrence rate in the 44 patients, including retransplantations and patients with pretransplant lamivudine resistance, was 11.5 % under combination prophylaxis. Recurrence was seen only in one of 39 patients (2.6 %) without preoperative lamivudine resistance, in contrast 4 out of 5 patients (80 %) with pre-existing lamivudine resistance suffered from early hepatitis B recurrence. The single patient without preoperative lamivudine resistance, who developed recurrence was pre-transplant HBV-DNA negative without lamivudine treatment, but a postoperative seroconversion to negative HBsAg could not be achieved. The overall 3 year patient survival rate was 91 % in the study population. One patient, who was retransplanted with preoperative lamivudine resistance, died 4.5 months after retransplantation due to hepatitis B recurrence and sepsis, three other patients died for reasons not related to hepatitis B recurrence. Combination prophylaxis was well tolerated in all patients and no severe side effects were observed.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Combination prophylaxis with hepatitis B immunoglobulin and lamivudine is safe and highly effective in prevention of HBV recurrence after liver transplantation, even in case of positive viral replication. In accordance with the results of other centers it should therefore be the standard regimen. However it fails in the majority of patients with preoperative evolution of YMDD mutations, in which the optimal management has to be determined yet. To minimize preoperative resistance formation universal preoperative antiviral treatment of HBV-DNA positive patients should be replaced by individualized indication for preoperative treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Seehofer</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General-, Visceral- and Transplant-Surgery, Charit√© Campus Virchow, Humboldt University of Berlin, Germany. daniel.seehofer@charite.de</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rayes</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Steinm√ºller</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>M√ºller</LastName>
                    <ForeName>A R</ForeName>
                    <Initials>AR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jonas</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Settmacher</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neuhaus</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berg</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neuhaus</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D023362">Evaluation Studies</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Z Gastroenterol</MedlineTA>
            <NlmUniqueID>0033370</NlmUniqueID>
            <ISSNLinking>0044-2771</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C045213">hepatitis B hyperimmune globulin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2T8Q726O95</RegistryNumber>
                <NameOfSubstance UI="D019259">Lamivudine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004279">DNA, Viral</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D024882">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006515">Hepatitis B virus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019694">Hepatitis B, Chronic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007136">Immunoglobulins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019259">Lamivudine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D016031">Liver Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011183">Postoperative Complications</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018894">Reverse Transcriptase Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>1</Month>
                <Day>29</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12215948</ArticleId>
            <ArticleId IdType="doi">10.1055/s-2002-33874</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25451574</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>12</Month>
            <Day>2</Day>
        </DateCreated>
        <DateRevised>
            <Year>2014</Year>
            <Month>12</Month>
            <Day>3</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7786</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>224C</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chemico-biological interactions</Title>
                <ISOAbbreviation>Chem. Biol. Interact.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sauchinone attenuates liver fibrosis and hepatic stellate cell activation through TGF-Œ≤/Smad signaling pathway.</ArticleTitle>
            <Pagination>
                <MedlinePgn>58-67</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S0009-2797(14)00293-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.cbi.2014.10.005</ELocationID>
            <Abstract>
                <AbstractText>Hepatic stellate cells (HSCs) are key mediators of fibrogenesis, and the regulation of their activation is now viewed as an attractive target for the treatment of liver fibrosis. Here, the authors investigated the ability of sauchinone, an active lignan found in Saururus chinensis, to regulate the activation of HSCs, to prevent liver fibrosis, and to inhibit oxidative stress in vivo and in vitro. Blood biochemistry and histopathology were assessed in CCl4-induced mouse model of liver fibrosis to investigate the effects of sauchinone. In addition, transforming growth factor-Œ≤1 (TGF-Œ≤1)-activated LX-2 cells (a human HSC line) were used to investigate the in vitro effects of sauchinone. Sauchinone significantly inhibited liver fibrosis, as indicated by decreases in regions of hepatic degeneration, inflammatory cell infiltration, and the intensity of Œ±-smooth muscle actin staining in mice. Sauchinone blocked the TGF-Œ≤1-induced phosphorylation of Smad 2/3 and the transcript levels of plasminogen activator inhibitor-1 and matrix metalloproteinase-2 as well as autophagy in HSCs. Furthermore, sauchinone inhibited oxidative stress, as assessed by stainings of 4-hydroxynonenal and nitrotyrosine: these events may have a role in its inhibitory effects on HSCs activation. Sauchinone attenuated CCl4-induced liver fibrosis and TGF-Œ≤1-induced HSCs activation, which might be, at least in part, mediated by suppressing autophagy and oxidative stress in HSCs.</AbstractText>
                <CopyrightInformation>Copyright ¬© 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Ju-Hee</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Oriental Medicine, Daegu Haany University, Daegu 706-828, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Jang</LastName>
                    <ForeName>Eun Jeong</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Oriental Medicine, Daegu Haany University, Daegu 706-828, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Seo</LastName>
                    <ForeName>Hye Lim</ForeName>
                    <Initials>HL</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Oriental Medicine, Daegu Haany University, Daegu 706-828, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Ku</LastName>
                    <ForeName>Sae Kwang</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Oriental Medicine, Daegu Haany University, Daegu 706-828, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Jong Rok</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Oriental Medicine, Daegu Haany University, Daegu 706-828, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Shin</LastName>
                    <ForeName>Soon Shik</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Oriental Medicine, Dongeui University, Busan 614-851, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Sun-Dong</ForeName>
                    <Initials>SD</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Oriental Medicine, Dongguk University, Gyeongju, Gyeongbuk 780-714, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Sang Chan</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Oriental Medicine, Daegu Haany University, Daegu 706-828, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Young Woo</ForeName>
                    <Initials>YW</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Oriental Medicine, Daegu Haany University, Daegu 706-828, Republic of Korea. Electronic address: ywkim@dhu.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType UI="">JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Chem Biol Interact</MedlineTA>
            <NlmUniqueID>0227276</NlmUniqueID>
            <ISSNLinking>0009-2797</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Carbon tetrachloride</Keyword>
            <Keyword MajorTopicYN="N">Hepatic stellate cells</Keyword>
            <Keyword MajorTopicYN="N">Liver fibrosis</Keyword>
            <Keyword MajorTopicYN="N">Sauchinone</Keyword>
            <Keyword MajorTopicYN="N">TGF-Œ≤1</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25451574</ArticleId>
            <ArticleId IdType="pii">S0009-2797(14)00293-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cbi.2014.10.005</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9688461</PMID>
        <DateCreated>
            <Year>1998</Year>
            <Month>10</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1998</Year>
            <Month>10</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0306-3623</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>31</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1998</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>General pharmacology</Title>
                <ISOAbbreviation>Gen. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of recombinant human serum albumin on ascites in rats with puromycin aminonucleoside-induced nephropathy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>209-14</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>1. Recombinant human serum albumin (rHSA) (1 g/kg) significantly decreased the weight of ascites in rats with puromycin aminonucleoside-induced nephropathy. 2. Furosemide (1-30 mg/kg) did not significantly reduce the weight of ascites in this model. 3. A combination of rHSA (1 g/kg) with furosemide (5 mg/kg) significantly decreased the weight of ascites in this model compared with furosemide alone. 4. In consideration of these results, rHSA can be a substitute for human serum albumin products prepared from human plasma in therapy for ascites or edema in furosemide-resistant nephrotic syndrome.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tsukada</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Central Research Laboratory, The Green Cross Corporation, Hirakata, Osaka, Japan. tsukada@yoshitomi.co.jp</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shintome</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsui</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsuchiyama</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maruyama</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuki</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hanada</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakamura</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Gen Pharmacol</MedlineTA>
            <NlmUniqueID>7602417</NlmUniqueID>
            <ISSNLinking>0306-3623</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004232">Diuretics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>58-60-6</RegistryNumber>
                <NameOfSubstance UI="D011692">Puromycin Aminonucleoside</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7LXU5N7ZO5</RegistryNumber>
                <NameOfSubstance UI="D005665">Furosemide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001201">Ascites</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004232">Diuretics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004353">Drug Evaluation, Preclinical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005665">Furosemide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009402">Nephrosis, Lipoid</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009997">Osmotic Pressure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011692">Puromycin Aminonucleoside</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012709">Serum Albumin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1998</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1998</Year>
                <Month>8</Month>
                <Day>4</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1998</Year>
                <Month>8</Month>
                <Day>4</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9688461</ArticleId>
            <ArticleId IdType="pii">S0306362398000020</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2934001</PMID>
        <DateCreated>
            <Year>1986</Year>
            <Month>01</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1986</Year>
            <Month>01</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0310-057X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1985</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anaesthesia and intensive care</Title>
                <ISOAbbreviation>Anaesth Intensive Care</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Diazepam mixed micelle--comparison with diazepam in propylene glycol and midazolam.</ArticleTitle>
            <Pagination>
                <MedlinePgn>352-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A mixed micelle formulation of diazepam was compared with midazolam and diazepam in propylene glycol for evidence of venous intolerance following IV injection. The overall incidence of venous morbidity was 17% for diazepam mixed micelle, 26% for midazolam and 90% for diazepam in propylene glycol. Diazepam mixed micelle is suggested as a preferable alternative to the standard formulation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Galletly</LastName>
                    <ForeName>D C</ForeName>
                    <Initials>DC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilson</LastName>
                    <ForeName>L F</ForeName>
                    <Initials>LF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Treuren</LastName>
                    <ForeName>B C</ForeName>
                    <Initials>BC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boon</LastName>
                    <ForeName>B P</ForeName>
                    <Initials>BP</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>AUSTRALIA</Country>
            <MedlineTA>Anaesth Intensive Care</MedlineTA>
            <NlmUniqueID>0342017</NlmUniqueID>
            <ISSNLinking>0310-057X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008823">Micelles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014677">Pharmaceutical Vehicles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011409">Propylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>12794-10-4</RegistryNumber>
                <NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q3JTX2Q7TU</RegistryNumber>
                <NameOfSubstance UI="D003975">Diazepam</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R60L0SM5BC</RegistryNumber>
                <NameOfSubstance UI="D008874">Midazolam</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001569">Benzodiazepines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003975">Diazepam</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006339">Heart Rate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008823">Micelles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008874">Midazolam</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014677">Pharmaceutical Vehicles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011409">Propylene Glycols</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013927">Thrombosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014680">Veins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1985</Year>
                <Month>11</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1985</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1985</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2934001</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
